Nancy Kahn, MD
Internal Medicine · New York, NYNPI 1649345299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Bausch Health US, LLC at 43.4% of the total. Reporting peaked in 2019 at $252 and has fallen 83.2% since, to $42 in 2022.
Across 22 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$187
- Radius Health, Inc.$66
- Novo Nordisk$61
- Merck$36
- Daiichi Sankyo Inc.$34
- Smith+Nephew$29
- plus $17 from 1 others
What the payments were for
- Food & beverage$430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 10 | $187 |
| Radius Health, Inc. | 3 | $66 |
| Novo Nordisk | 3 | $61 |
| Merck | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Smith+Nephew | 1 | $29 |
| Gilead | 1 | $17 |
How this compares
$430 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $19,485 |
| TrulicityDulaglutide | 13 | $14,332 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,500 |
| Metoprolol Succinate | 49 | $1,389 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,317 |
| Atorvastatin Calcium | 167 | $1,295 |
| Levothyroxine Sodium | 98 | $1,054 |
| Amlodipine Besylate | 126 | $729 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 15 | $682 |
| Losartan Potassium | 84 | $607 |
| Hydrochlorothiazide | 154 | $574 |
| Bupropion XlBupropion Hcl | 12 | $449 |
| Metformin Hcl | 63 | $412 |
| Escitalopram Oxalate | 34 | $406 |
| Lisinopril | 57 | $388 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.